A meta-analysis of adverse events in combination EGFR TKI and ICIs in advanced EGFR-mutant NSCLC confirmed that the joint incidences of gastrointestinal grade 3 skin and adverse events and ILD were significantly higher in combination therapy than in osimertinib monotherapy, limiting future clinical development of this association [100]. This evidence concerns the gene EGFR and interstitial lung disease.